{"id":494823,"date":"2021-05-18T07:05:43","date_gmt":"2021-05-18T11:05:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/"},"modified":"2021-05-18T07:05:43","modified_gmt":"2021-05-18T11:05:43","slug":"bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/","title":{"rendered":"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MINNEAPOLIS<\/span>, May 18, 2021<\/span> \/PRNewswire\/ —\u00a0Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform<\/a>, which is currently sold for research use only, allows users to perform high-quality immunoassays with no manual intervention, delivering results in just 90 minutes and requiring only 25 \u00b5L of sample. Factory calibration of each Simple Plex assay cartridge minimizes setup time and user error. Setting up an assay simply requires loading diluted samples into the cartridge. Once loaded, Ella performs every step of the immunoassay automatically, from wash steps to final quantification of results.<\/p>\n

\n

\n
\n \"Bio-Techne\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Under the terms of this collaboration, Bio-Techne will provide Ella instruments and Simple Plex assay cartridges, which are run on the Ella platform, for customized ophthalmology related\u00a0evaluations. Narayana Nethralaya plans to conduct diagnostic clinical trials in India<\/span>, with the aim of filing for regulatory approval using Ella as a diagnostic device for ophthalmic applications. <\/p>\n

“This collaboration with Narayana Nethralaya potentially expands Ella’s capabilities as a tool for diagnosing ophthalmology disorders in India<\/span>,” commented Chuck Kummeth<\/span>, Bio-Techne’s President and Chief Executive Officer.\u00a0 “We believe Ella has great potential as a clinical diagnostic system and look forward to pursuing these applications in the future.” <\/p>\n

“The use of Ella during the diagnostic development process provides significant benefits over manual ELISA based approaches, enabling faster biomarker screening,” commented Dr. Arkasubhra Ghosh, Director of GROW Laboratory at Narayana Nethralaya.. “We are excited to utilize Ella to provide a better solution for differential diagnosis and monitoring of patients with ophthalmic disorders”, said Dr. Rohit Shetty<\/span>, Narayana Nethralaya’s Vice-Chairman.<\/p>\n

More information on ELLA can be found at
https:\/\/www.proteinsimple.com\/ella.html<\/a><\/b><\/p>\n

\n About Bio-Techne Corporation<\/a>\u00a0(NASDAQ: TECH) <\/p>\n

\n Investor Relations<\/b>\n <\/p>\n

Contact: David Clair<\/span>, Senior Director, Investor Relations and Corporate Development
Phone: 612-656-4416
Email: david.clair@bio-techne.com<\/a><\/p>\n

\n About Narayana Nethralaya
<\/b>Established in the year 1982 as an eye clinic at Srirampuram, Bangalore<\/span>, by Dr. K. Bhujang Shetty, a leading luminary in the field of ophthalmic health care, Narayana Nethralaya has achieved remarkable growth in the last 39 years, becoming one of the top tertiary eye hospitals serving close to half a million patients annually. A testimony to his determination and hard work, Dr. Shetty’s vision of establishing a ‘dream center’ of service, eye care training, personalised treatments and research is now a reality.<\/p>\n

For more information visit https:\/\/www.narayananethralaya.org<\/a><\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications-301293276.html<\/a><\/p>\n

SOURCE Bio-Techne Corporation<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire MINNEAPOLIS, May 18, 2021 \/PRNewswire\/ —\u00a0Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-quality immunoassays with no manual intervention, delivering results in just 90 minutes and requiring only 25 \u00b5L of sample. Factory calibration of each Simple Plex assay cartridge minimizes setup time and user error. Setting up an assay simply requires loading diluted samples into the cartridge. Once loaded, Ella performs every step of the immunoassay automatically, from wash steps to final quantification of results. Under the terms of this collaboration, Bio-Techne will … <\/p>\n

Continue reading “Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-494823","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MINNEAPOLIS, May 18, 2021 \/PRNewswire\/ —\u00a0Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-quality immunoassays with no manual intervention, delivering results in just 90 minutes and requiring only 25 \u00b5L of sample. Factory calibration of each Simple Plex assay cartridge minimizes setup time and user error. Setting up an assay simply requires loading diluted samples into the cartridge. Once loaded, Ella performs every step of the immunoassay automatically, from wash steps to final quantification of results. Under the terms of this collaboration, Bio-Techne will … Continue reading "Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-18T11:05:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/363268\/Bio_Techne__Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications\",\"datePublished\":\"2021-05-18T11:05:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/\"},\"wordCount\":434,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/363268\\\/Bio_Techne__Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/\",\"name\":\"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/363268\\\/Bio_Techne__Logo.jpg\",\"datePublished\":\"2021-05-18T11:05:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/363268\\\/Bio_Techne__Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/363268\\\/Bio_Techne__Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/","og_locale":"en_US","og_type":"article","og_title":"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications - Market Newsdesk","og_description":"PR Newswire MINNEAPOLIS, May 18, 2021 \/PRNewswire\/ —\u00a0Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-quality immunoassays with no manual intervention, delivering results in just 90 minutes and requiring only 25 \u00b5L of sample. Factory calibration of each Simple Plex assay cartridge minimizes setup time and user error. Setting up an assay simply requires loading diluted samples into the cartridge. Once loaded, Ella performs every step of the immunoassay automatically, from wash steps to final quantification of results. Under the terms of this collaboration, Bio-Techne will … Continue reading \"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-18T11:05:43+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/363268\/Bio_Techne__Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications","datePublished":"2021-05-18T11:05:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/"},"wordCount":434,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/363268\/Bio_Techne__Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/","name":"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/363268\/Bio_Techne__Logo.jpg","datePublished":"2021-05-18T11:05:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/363268\/Bio_Techne__Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/363268\/Bio_Techne__Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=494823"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494823\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=494823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=494823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=494823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}